259 related articles for article (PubMed ID: 21766440)
1. Evolving knowledge of the teratogenicity of medications in human pregnancy.
Adam MP; Polifka JE; Friedman JM
Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):175-82. PubMed ID: 21766440
[TBL] [Abstract][Full Text] [Related]
2. Human teratogens: update 2010.
Holmes LB
Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
[TBL] [Abstract][Full Text] [Related]
3. Potential human teratogenicity of frequently prescribed drugs.
Friedman JM; Little BB; Brent RL; Cordero JF; Hanson JW; Shepard TH
Obstet Gynecol; 1990 Apr; 75(4):594-9. PubMed ID: 2314777
[TBL] [Abstract][Full Text] [Related]
4. Teratogenicity of recently introduced medications in human pregnancy.
Lo WY; Friedman JM
Obstet Gynecol; 2002 Sep; 100(3):465-73. PubMed ID: 12220765
[TBL] [Abstract][Full Text] [Related]
5. Monitoring for teratogenic signals: pregnancy registries and surveillance methods.
Howard TB; Tassinari MS; Feibus KB; Mathis LL
Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):209-14. PubMed ID: 21766431
[TBL] [Abstract][Full Text] [Related]
6. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?
Law R; Bozzo P; Koren G; Einarson A
Can Fam Physician; 2010 Mar; 56(3):239-41. PubMed ID: 20228306
[TBL] [Abstract][Full Text] [Related]
7. Knowledge transfer and translation: examining how teratogen information is disseminated.
Shahin I; Einarson A
Birth Defects Res A Clin Mol Teratol; 2011 Nov; 91(11):956-61. PubMed ID: 21948595
[TBL] [Abstract][Full Text] [Related]
8. Provision of potentially teratogenic medications to female veterans of childbearing age.
Schwarz EB; Longo LS; Zhao X; Stone RA; Cunningham F; Good CB
Med Care; 2010 Sep; 48(9):834-42. PubMed ID: 20706159
[TBL] [Abstract][Full Text] [Related]
9. Risk classification systems for drug use during pregnancy: are they a reliable source of information?
Addis A; Sharabi S; Bonati M
Drug Saf; 2000 Sep; 23(3):245-53. PubMed ID: 11005706
[TBL] [Abstract][Full Text] [Related]
10. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.
Yang T; Walker MC; Krewski D; Yang Q; Nimrod C; Garner P; Fraser W; Olatunbosun O; Wen SW
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):270-7. PubMed ID: 18181228
[TBL] [Abstract][Full Text] [Related]
11. ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects.
Friedman JM
Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):670-6. PubMed ID: 22786781
[TBL] [Abstract][Full Text] [Related]
12. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach.
Nava-Ocampo AA; Koren G
Clin Obstet Gynecol; 2007 Mar; 50(1):123-31. PubMed ID: 17304029
[TBL] [Abstract][Full Text] [Related]
13. The estimation of human teratogenic/fetotoxic risk of exposures to drugs on the basis of Hungarian experience: a critical evaluation of clinical and epidemiological models of human teratology.
Czeizel AE
Expert Opin Drug Saf; 2009 May; 8(3):283-303. PubMed ID: 19505262
[TBL] [Abstract][Full Text] [Related]
14. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women.
Cleary BJ; Butt H; Strawbridge JD; Gallagher PJ; Fahey T; Murphy DJ
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):408-17. PubMed ID: 20099251
[TBL] [Abstract][Full Text] [Related]
15. [Consultation activity of two Slovak centres for pharmacotherapy during pregnancy and lactation].
Tisonová J; Magulová L; Göböová M; Wawruch M; Lassánová M; Bozeková L; Kriska M
Cas Lek Cesk; 2006; 145(2):154-7; discussion 158-9. PubMed ID: 16521407
[TBL] [Abstract][Full Text] [Related]
16. [Drugs during pregnancy and breastfeeding: new risk categories--antibiotics as a model].
Bertsche T; Haas M; Oberwittler H; Haefeli WE; Walter-Sack I
Dtsch Med Wochenschr; 2006 May; 131(18):1016-22. PubMed ID: 16673226
[TBL] [Abstract][Full Text] [Related]
17. The importance of dysmorphology in the identification of new human teratogens.
Jones KL; Carey JC
Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):188-94. PubMed ID: 21766438
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research.
Lisi A; Botto LD; Robert-Gnansia E; Castilla EE; Bakker MK; Bianca S; Cocchi G; de Vigan C; Dutra Mda G; Horacek J; Merlob P; Pierini A; Scarano G; Sipek A; Yamanaka M; Mastroiacovo P
Reprod Toxicol; 2010 Jul; 29(4):433-42. PubMed ID: 20347959
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing surveillance for drug safety in pregnancy: the Organization of Teratology Information Services project.
Felix RJ; Jones KL; Johnson KA; McCloskey CA; Chambers CD;
Birth Defects Res A Clin Mol Teratol; 2004 Dec; 70(12):944-7. PubMed ID: 15570610
[TBL] [Abstract][Full Text] [Related]
20. Risk of drug-induced congenital defects.
De Santis M; Straface G; Carducci B; Cavaliere AF; De Santis L; Lucchese A; Merola AM; Caruso A
Eur J Obstet Gynecol Reprod Biol; 2004 Nov; 117(1):10-9. PubMed ID: 15474237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
